Positive peritoneal fluid fungal cultures in postoperative peritonitis after bariatric surgery

N Zappella1, M Desmard2, C Chochillon3

  • 1Département d'Anesthésie Réanimation, Université Paris Diderot Sorbonne Cite, APHP, CHU Bichat-Claude Bernard, France.

Insights

Postoperative peritonitis after bariatric surgery often involves Candida infections, including resistant strains. Early antifungal treatment is recommended for better outcomes in intensive care unit patients.

Area of Science:

  • Surgical Complications
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Postoperative peritonitis (POP) is a frequent complication following bariatric surgery (BS).
  • The role of fungal infections, particularly Candida, in POP requires further investigation.
  • Intensive care unit (ICU) management of POP necessitates understanding specific etiological factors.

Purpose of the Study:

  • To evaluate the significance of positive fungal cultures in patients with POP after BS admitted to the ICU.
  • To compare clinical features and outcomes between Candida-positive and Candida-negative POP patients.
  • To identify risk factors associated with mortality in this patient cohort.

Main Methods:

  • Retrospective analysis of patients with POP following BS admitted to the ICU.
  • Comparison of clinical data and microbiological findings between patients with and without Candida infection.
  • Identification of Candida species and assessment of antifungal resistance, including fluconazole resistance in Candida glabrata.

Main Results:

  • Candida was isolated in 41% of POP cases, frequently in late-onset peritonitis.
  • Candida infections were often associated with multidrug-resistant bacteria.
  • Mortality in the ICU was 19.6%, with diabetes and superobesity identified as risk factors.

Conclusions:

  • Candida infections are prevalent in postoperative peritonitis after bariatric surgery.
  • Fluconazole-resistant Candida strains, such as Candida glabrata, were observed.
  • Empirical use of broad-spectrum antifungal agents is encouraged for managing POP in BS patients.